Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
For the first time research throws a proper light on the association between the Vitamin D and the response of the immune system for the cancer cells ...
We have a lot of data on the ability of the immune system to recognize and control ovarian cancer. Data from our preclinical studies using stem cells ...
... emphasizing mainly on engineered autologous T cell therapy (eACT™) products which help in treatingcancer by enhancing the immune system's ...
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing ... -MarketWatch
“Genetically engineering our patients' immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting ...
... more durable responses, including certain immune system characteristics that may ... regimen, CRS-207 and GVAX Pancreas, in pancreatic cancer.
Almost half of patients with borderline resectable or locally advanced pancreaticcancer had objective responses to treatment with PF-04136309, ...
The incidence and mortality of pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States, are both on the rise.
An analysis of the per-protocol population in the phase III NAPOLI-1 trial supports the benefits of adding MM-398 to 5-fluorouracil plus leucovorin ...
Pancreatic cancer is a devastating disease. With a ten-year survival rate of just 1%, it has the poorest prognosis of all solid tumours. The main reason ...
TEN ways to keep cancer at bay..why take the chance? Last week researchers said apart from breast cancer and pancreatic cancer - the disease is ...
The company's therapy ups the immune response of cancer patients, ... “Our approach can be categorized as a generic boost to the immune system,” ...
"These gene mutations, as we call them, allow cancer cells to evade the immune system," he says, "and to produce products that allow the cancer cells ...
Aduro Biotech Inc. today announced that seven pancreatic cancer patients treated with its combination ... with more durable responses including certain immune system characteristics that may potentially provide predicative value on ...
CLL is a cancer of the white blood cells often found in bone marrow. ... may stimulate the immune system to work harder or smarter to attack cancer ...
Although activating the immune system as a therapeutic approach in cancer has long been a cooperative goal between immunology and oncology, ...
Cancer cells proliferate in part because they block or trick the body's immune system from recognizing and attacking them, forming the foundation of ...
In this phase III analysis, patients with metastatic pancreatic cancer were randomly assigned to MM-398 at 120 mg/m2 (n = 151), 5-FU/leucovorin (n ...
Analysis of NAPOLI-1 Study Shows MM-398 Benefit in Metastatic Pancreatic Cancer - Curetoday.com (press release)
They devised a way of screening compounds for the desired effect and have identified a compound that shows promise in fighting pancreatic cancer.
Aduro Biotech Inc. today announced that seven pancreatic cancer patients treated with its combination immuno-oncology regimen in a 93-patient ...
Cancer News in Science Daily
Existing cancer therapies are geared toward massacring tumor cells, but researchers propose a different strategy: subtly hardening cancer cells to prevent them from invading new areas of the body. They devised a way of screening compounds for the desired effect and have identified a compound that shows promise in fighting pancreatic cancer.
With the goal of making it easier for surgeons to detect malignant tissue during surgery and hopefully reduce the rate of cancer recurrence, scientists have invented a new imaging system that causes tumors to “light up” when a hand-held laser is directed at them.
Multiple myeloma is a malignant disease characterized by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.
Tambahkan Komentar